文献速递临床试验与 GCP流行病学与生物统计

SMARTscreen试验:一项随机对照试验,研究全科医生背书的叙事短信能否提高澳大利亚国家肠癌筛查项目的参与率

The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
PubMed 文献 · Trials · 2022-01-12

该试验在澳大利亚维多利亚州西部招募20家全科诊所进行整群随机对照试验,按1:1随机分为对照组和干预组,通过现有全科软件识别未来一个月内应收到国家肠癌筛查项目(NBCSP)试剂盒的50至60岁患者。干预组在患者收到试剂盒前发送含全科医生背书和叙事信息链接的短信。主要结局是短信发送后12个月内电子病历记录中完成粪便隐血试验(FOBT)的合格患者比例差异。

要点

  • 目前澳大利亚50至74岁人群仅44%完成NBCSP。
  • 该实效性试验检验短信干预能否提高NBCSP参与率。
  • 需1400名合格患者以80%把握度、双侧5%显著性水平检测干预组较对照组结直肠癌筛查参与率提高10%。

核心结论

  • 该实效性试验将提供短信叙事干预提高NBCSP参与率的初步试验证据,结果将为是否需要设计更大规模多州试验以确定成本效果和未来实施提供依据。

研究设计与样本

  • 在澳大利亚维多利亚州西部招募20家全科诊所参与整群随机对照试验,按1:1比例随机分配至对照组或干预组。
  • 使用现有全科软件识别未来一个月内应收到NBCSP试剂盒的50至60岁患者。
  • 需1400名合格患者以80%把握度、双侧5%显著性水平检测干预组较对照组结直肠癌筛查参与率提高10%。

关键数值与推荐

  • 主要结局为短信发送后12个月内电子病历记录的干预组与对照组完成粪便隐血试验(FOBT)的合格患者比例差异。
  • 干预短信包含全科医生背书及叙事信息链接,内容涉及完成NBCSP试剂盒的益处和操作说明,由干预组全科诊所在患者收到试剂盒前发送。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing participation in the Australian National Bowel Cancer Screening Program (NBCSP) is the most efficient and cost-effective way of reducing mortality associated with colorectal cancer by detecting and treating early-stage disease. Currently, only 44% of Australians aged 50-74 years complete the NBCSP. This efficacy trial aims to test whether this SMS intervention is an effective method for increasing participation in the NBCSP. Furthermore, a process evaluation will explore the barriers and facilitators to sending the SMS from general practice. METHODS: We will recruit 20 general practices in the western region of Victoria, Australia to participate in a cluster randomised controlled trial. General practices will be randomly allocated with a 1:1 ratio to either a control or intervention group. Established general practice software will be used to identify patients aged 50 to 60 years old who are due to receive a NBCSP kit in the next month. The SMS intervention includes GP endorsement and links to narrative messages about the benefits of and instructions on how to complete the NBCSP kit. It will be sent from intervention general practices to eligible patients prior to receiving the NBCSP kit. We require 1400 eligible patients to provide 80% power with a two-sided 5% significance level to detect a 10% increase in CRC screening participation in the intervention group compared to the control group. Our primary outcome is the difference in the proportion of eligible patients who completed a faecal occult blood test (FOBT) between the intervention and control group for up to 12 months after the SMS was sent, as recorded in their electronic medical record (EMR). A process evaluation using interview data collected from general practice staff (GP, practice managers, nurses) and patients will explore the feasibility and acceptability of sending and receiving a SMS to prompt completing a NBCSP kit. DISCUSSION: This efficacy trial will provide initial trial evidence of the utility of an SMS narrative intervention to increase participation in the NBCSP. The results will inform decisions about the need for and design of a larger, multi-state trial of this SMS intervention to determine its cost-effectiveness and future implementation. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12620001020976 . Registered on 17 October 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wood A, Emery JD, Jenkins M, et al. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program. Trials. 2022. PMID: 35022080. doi:10.1186/s13063-021-05877-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。